Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of ABBV-722 and Transporter Cocktail Substrates in Healthy Adults
NCT07567781Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABBV-722, sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events up to 56 Days, Maximum Observed Plasma Concentration and 4 more. Started Apr 2026; status: completed.
02
Drugs
ABBV-722
Beyond the preview
Go deeper on NCT07567781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567781.